Physician profile
Sanjosh Singh
NPI 1801086806
$35,393.23
in general payments reported to CMS, 2019-2025
36 companies · $4,680 in 2025
The $4,680 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,631 · 2020: $2,006 · 2021: $3,595 · 2022: $3,072 · 2023: $4,245 · 2024: $14K · 2025: $4,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $6,394 · Honoraria: $3,600 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,697.46 |
| Consulting Fee | $6,394.27 |
| Honoraria | $3,600.00 |
| Education | $397.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $10,635.57 | 2019-2025 | Aklief, Nemluvio, Tri-Luma |
| Parapro, LLC | $3,600.00 | 2024 | Natroba |
| Regeneron Healthcare Solutions, INC. | $2,492.74 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $1,693.25 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,469.79 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,377.69 | 2019-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,297.01 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,267.96 | 2019-2024 | Jublia, Arazlo, Duobrii |
| Genzyme Corporation | $1,097.01 | 2021-2025 | |
| Amgen INC. | $1,020.86 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $1,010.18 | 2019-2025 | |
| Epi Health, LLC | $991.91 | 2019-2022 | |
| Dermavant Sciences, INC. | $885.77 | 2022-2024 | Vtama |
| Incyte Corporation | $777.13 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $722.50 | 2022-2025 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $658.79 | 2019-2025 | |
| Ucb, INC. | $630.60 | 2022-2025 | Bimzelx |
| Leo Pharma INC. | $593.27 | 2019-2025 | Adbry, Anzupgo |
| Avita Medical Americas, LLC | $500.00 | 2023 | Recell |
| Vyne Pharmaceuticals INC. | $496.68 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $348.17 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $325.69 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Scientific Affairs, LLC | $249.66 | 2020 | |
| Organon LLC | $220.86 | 2025 | Vtama |
| Botanix Sb INC | $212.04 | 2025 | Sofdra |
| Almirall LLC | $206.89 | 2019 | |
| Celgene Corporation | $140.00 | 2019 | |
| Biofrontera INC. | $109.36 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Promius Pharma LLC | $88.95 | 2019 | |
| Mylan Institutional INC. | $75.68 | 2023 | Hulio, Fulphila |
| Taro Pharmaceuticals USA, INC. | $60.67 | 2019 | |
| Journey Medical Corporation | $54.16 | 2022 | |
| Smith+Nephew, INC. | $25.48 | 2019 | |
| Kyowa Kirin, INC. | $20.80 | 2022 | |
| Encore Dermatology INC. | $20.58 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.53 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjosh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.